The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study - Scorecard - MDSpire

The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study

  • By

  • Aspasia Manta

  • Afroditi Roumpou

  • Maria Gerogianni

  • Roubini Zakopoulou

  • Kimon Tzannis

  • Areti Mamali

  • Vasiliki Malamatini

  • Konstantina Kakogianni

  • Aristotelis Bamias

  • Melpomeni Peppa

  • June 30, 2026

  • 0 min

Share

Clinical Scorecard: Examining the Prognostic Role of Metabolic Syndrome on Survival Rates in Urothelial Carcinoma: A Retrospective Analysis

At a Glance

CategoryDetail
ConditionUrothelial Carcinoma
Key MechanismsMetabolic syndrome (MetS) includes obesity, hypertension, dyslipidemia, and hyperglycemia, impacting cancer outcomes.
Target PopulationPatients diagnosed with urothelial carcinoma (UC), particularly those with metabolic syndrome.
Care SettingOncology Department of Attikon University Hospital, Athens, Greece.

Key Highlights

  • MetS was present in 43.8% of the studied UC patients.
  • MetS was associated with poorer overall survival (OS) and progression-free survival (PFS).
  • Diabetes was the strongest predictor of adverse outcomes in UC patients.
  • Hypertension independently predicted worse OS.
  • Obesity and dyslipidemia were not associated with survival outcomes.

Guideline-Based Recommendations

Diagnosis

  • Histologically confirm urothelial carcinoma.
  • Assess for metabolic syndrome using defined criteria.

Management

  • Consider metabolic health optimization in UC patients.

Monitoring & Follow-up

  • Regularly evaluate overall survival and progression-free survival in UC patients with MetS.

Risks

  • Increased risk of poorer survival outcomes associated with metabolic syndrome.

Patient & Prescribing Data

112 patients with urothelial carcinoma diagnosed between January 2018 and February 2024.

Focus on managing metabolic syndrome components, particularly diabetes and hypertension, to potentially improve survival outcomes.

Clinical Best Practices

  • Utilize the AJCC criteria for staging urothelial carcinoma.
  • Implement complete case analysis for missing data in clinical studies.

Related Resources & Content

Original Source(s)

Related Content